Pieter J.A. Eichhorn

Targeting USP14 disrupts lipid metabolism and survival pathways in diffuse large B-cell lymphoma (DLBCL)

Abstract Proteasome inhibitors have transformed cancer therapy in certain settings. However, their overall effectiveness is often limited as residual proteasome function is retained through the overexpression of ubiquitin-specific protease 14 (USP14), a proteasome-associated deub...